SG11201805434UA - Bacterial ghosts for the treatment of cancer - Google Patents
Bacterial ghosts for the treatment of cancerInfo
- Publication number
- SG11201805434UA SG11201805434UA SG11201805434UA SG11201805434UA SG11201805434UA SG 11201805434U A SG11201805434U A SG 11201805434UA SG 11201805434U A SG11201805434U A SG 11201805434UA SG 11201805434U A SG11201805434U A SG 11201805434UA SG 11201805434U A SG11201805434U A SG 11201805434UA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- bacterial ghosts
- ghosts
- bacterial
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281836P | 2016-01-22 | 2016-01-22 | |
| EP16152445.9A EP3195878A1 (en) | 2016-01-22 | 2016-01-22 | Bacterial ghosts for the treatment of cancer |
| PCT/EP2017/051218 WO2017125564A1 (en) | 2016-01-22 | 2017-01-20 | Bacterial ghosts for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805434UA true SG11201805434UA (en) | 2018-08-30 |
Family
ID=55398179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805434UA SG11201805434UA (en) | 2016-01-22 | 2017-01-20 | Bacterial ghosts for the treatment of cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10772944B2 (en) |
| EP (2) | EP3195878A1 (en) |
| CN (1) | CN108472352B (en) |
| AU (1) | AU2017208581A1 (en) |
| BR (1) | BR112018014723A2 (en) |
| CA (1) | CA3011003A1 (en) |
| LT (1) | LT3405213T (en) |
| SG (1) | SG11201805434UA (en) |
| WO (1) | WO2017125564A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324956A (en) * | 2018-03-06 | 2018-07-27 | 东北农业大学 | It is a kind of using Escherichia coli bacterium shadow as the preparation method of carrier load taxol drug |
| CN110859859A (en) * | 2019-11-08 | 2020-03-06 | 四川大学华西医院 | Anti-tumor composition containing fixed bacteria and application thereof |
| CN110951663A (en) * | 2019-12-26 | 2020-04-03 | 深圳市前海金卓生物技术有限公司 | Recombinant bacterium for expressing PD-1 antibody and construction method and application thereof |
| WO2021151450A1 (en) * | 2020-01-29 | 2021-08-05 | Ahmed Sameh Rabea Mohamed | Targeted drug delivery system using bacterial ghosts of salmonella toward hepatic cancer cells |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4117125A (en) | 1977-06-24 | 1978-09-26 | Smithkline Corporation | 7-Acylamino-3-[1-[2-(carboxymethylamino]ethyl) tetrazol-5-ylthiomethyl]-3-cephem-4-carboxylic acids |
| DE19732829A1 (en) | 1997-07-30 | 1999-02-04 | Lubitz Werner Prof Dr | Secretion of carrier-bound proteins in the periplasm and in the extracellular space |
| US6573368B2 (en) * | 1998-12-28 | 2003-06-03 | Corixa Corporation | Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| DE19909770A1 (en) | 1999-03-05 | 2000-09-07 | Werner Lubitz | Bacterial ghosts as carrier and targeting vehicles |
| DE10003241A1 (en) | 2000-01-26 | 2001-08-02 | Werner Lubitz | Sealing bacterial ghosts |
| US7037500B1 (en) | 2000-09-08 | 2006-05-02 | The Trustees Of Columbia University In The City Of New York | Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity |
| EP1404808B1 (en) | 2001-07-11 | 2010-03-31 | Prof. Dr. Lubitz, Werner | Nucleic acid free ghost preparations |
| US7465454B2 (en) | 2002-12-16 | 2008-12-16 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| ES2401706T3 (en) | 2005-07-27 | 2013-04-23 | Eli Lilly And Company | A method of treating cancer cells to create a modified cancer cell that elicits an immunogenic response |
| US20110172826A1 (en) | 2005-12-14 | 2011-07-14 | Amodei Dario G | Device including altered microorganisms, and methods and systems of use |
| US7736642B2 (en) | 2006-02-02 | 2010-06-15 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| US20080031900A1 (en) | 2006-06-30 | 2008-02-07 | Baylor Research Institute | Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells |
| EP1897557A1 (en) | 2006-09-07 | 2008-03-12 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of glycolipids as adjuvants |
| CN102224237B (en) | 2008-01-18 | 2014-03-12 | 沃纳·卢比茨 | Bacterial ghost (BG) production process using beta-propiolactone (BLP) for final inactivation |
| JP5759980B2 (en) | 2009-04-17 | 2015-08-05 | グローブイミューン，インコーポレイテッド | Combination of immunotherapy compositions for cancer and infectious diseases |
| US9415017B2 (en) * | 2010-08-06 | 2016-08-16 | Werner Lubitz | Bacterial ghosts for mediating innate immunity |
| PL2591798T3 (en) | 2011-11-09 | 2015-04-30 | Werner Lubitz | Vaccine for use in tumor immunotherapy |
| PT3702373T (en) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| GB201322725D0 (en) * | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| KR102130600B1 (en) | 2014-07-03 | 2020-07-08 | 베이진 엘티디 | Anti-PD-L1 Antibodies and Their Use as Therapeutics and Diagnostics |
-
2016
- 2016-01-22 EP EP16152445.9A patent/EP3195878A1/en not_active Withdrawn
-
2017
- 2017-01-20 LT LTEP17700708.5T patent/LT3405213T/en unknown
- 2017-01-20 US US16/071,958 patent/US10772944B2/en active Active
- 2017-01-20 WO PCT/EP2017/051218 patent/WO2017125564A1/en active Application Filing
- 2017-01-20 CN CN201780007546.1A patent/CN108472352B/en active Active
- 2017-01-20 CA CA3011003A patent/CA3011003A1/en not_active Abandoned
- 2017-01-20 BR BR112018014723A patent/BR112018014723A2/en not_active IP Right Cessation
- 2017-01-20 EP EP17700708.5A patent/EP3405213B1/en active Active
- 2017-01-20 AU AU2017208581A patent/AU2017208581A1/en not_active Abandoned
- 2017-01-20 SG SG11201805434UA patent/SG11201805434UA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3405213T (en) | 2021-08-10 |
| WO2017125564A1 (en) | 2017-07-27 |
| AU2017208581A1 (en) | 2018-07-12 |
| US20190030146A1 (en) | 2019-01-31 |
| CN108472352B (en) | 2022-10-14 |
| CN108472352A (en) | 2018-08-31 |
| BR112018014723A2 (en) | 2018-12-11 |
| EP3405213A1 (en) | 2018-11-28 |
| US10772944B2 (en) | 2020-09-15 |
| EP3195878A1 (en) | 2017-07-26 |
| CA3011003A1 (en) | 2017-07-27 |
| EP3405213B1 (en) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1247202A1 (en) | Compounds for the treatment of cancer | |
| IL264674B1 (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| IL259996A (en) | Combinations for the treatment of cancer | |
| EP3307240A4 (en) | Combination therapy for the treatment of cancer | |
| HUE053654T2 (en) | Combinations of fgfr- and cmet-inhibitors for the treatment of cancer | |
| EP3359192A4 (en) | Combination therapy for the treatment of cancer | |
| EP3432888A4 (en) | Treatment of cancer with tg02 | |
| LT3473263T (en) | Combined preparations for the treatment of cancer | |
| EP3474854A4 (en) | Cancer treatment combinations | |
| EP3548028A4 (en) | Treatment of cancer | |
| EP3490561A4 (en) | Combinations for the treatment of cancer | |
| EP3383497A4 (en) | Novel antibodies for the treatment of cancers | |
| EP3352586A4 (en) | Nutritional treatment for cancer | |
| EP3503887A4 (en) | Combinations for the treatment of cancer | |
| EP3472623A4 (en) | Exosome-guided treatment of cancer | |
| GB201706451D0 (en) | Cancer treatment | |
| SG11201805434UA (en) | Bacterial ghosts for the treatment of cancer | |
| EP3548007A4 (en) | Methods for the treatment of cancer | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| HK1251794A1 (en) | Cancer treatment | |
| EP3484477A4 (en) | Treatment of cancer | |
| EP3180011A4 (en) | Immunotherapy for the treatment of cancer | |
| EP3576791A4 (en) | Calreticulin-mediated cancer treatment | |
| GB201707864D0 (en) | Platinum-reistant cancer treatment | |
| PL3630754T3 (en) | Isoindoline-acetylene compounds for the treatment of cancer |